Mean Platelet Volume and TXA2 Levels in Patients With Polycystic Ovary Syndrome (PCOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01538602
Recruitment Status : Completed
First Posted : February 24, 2012
Last Update Posted : February 24, 2012
Information provided by (Responsible Party):
AGUNCO Obstetrics and Gynecology Centre

Brief Summary:
Polycystic ovary syndrome (PCOS)is closely associated with insulin resistance and hyperinsulinemia as well as with increased incidence in diabetes, hypertension, dyslipidemia and atherosclerosis. Indeed, subjects with PCOS were reported to carry an increased long-term cardiovascular risk, among others. Aiming to correlate the mean platelet volume, the thromboxane A2 level and the PCOS, an observational study was planned. Clinical evaluation of metabolic outcomes in PCOS patients is compared to a placebo group.

Condition or disease
Polycystic Ovary Syndrome

Study Type : Observational
Observational Model: Case-Only
Time Perspective: Prospective

Resource links provided by the National Library of Medicine

PCOS patients
Healthy volunteers

Primary Outcome Measures :
  1. Mean platelet volume
  2. Thromboxane A2

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Sampling Method:   Non-Probability Sample
Study Population

Inclusion Criteria:

  • Women fulfilled two out of three diagnostic criteria for PCOS

Exclusion Criteria:

  • Pre-existing secondary endocrine disorders
  • History of hypertension, diabetes mellitus or cardiovascular disorders
  • Pharmacologic treatment in the last 6 months before entering the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01538602

Istituto di Patologia Ostetrica e Ginecologica
Catania, Italy
Sponsors and Collaborators
AGUNCO Obstetrics and Gynecology Centre

Responsible Party: AGUNCO Obstetrics and Gynecology Centre Identifier: NCT01538602     History of Changes
Other Study ID Numbers: MPV_PCOS
First Posted: February 24, 2012    Key Record Dates
Last Update Posted: February 24, 2012
Last Verified: February 2012

Keywords provided by AGUNCO Obstetrics and Gynecology Centre:
cardiovascular disorders

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Pathologic Processes
Ovarian Cysts
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases